Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conatus Pharmaceuticals CNAT

Healthcare Biotechnology
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes... see more

Recent & Breaking News (NDAQ:CNAT)

Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

GlobeNewswire November 5, 2019

Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates

GlobeNewswire August 6, 2019

Conatus to Explore Strategic Alternatives and Implement Restructuring Plan

GlobeNewswire June 24, 2019

Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis

GlobeNewswire June 24, 2019

Conatus Pharmaceuticals Reports First Quarter 2019 Financial Results and Program Updates

GlobeNewswire May 2, 2019

Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

GlobeNewswire April 30, 2019

Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

GlobeNewswire April 15, 2019

Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

GlobeNewswire April 2, 2019

The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead

Benzinga.com  March 29, 2019

60 Biggest Movers From Friday

Benzinga.com  March 25, 2019

Mid-Afternoon Market Update: Dow Down Over 300 Points; JinkoSolar Shares Fall After Q4 Results

Benzinga.com  March 22, 2019

Mid-Morning Market Update: Markets Open Lower; Hibbett Sports Beats Q4 Estimates

Benzinga.com  March 22, 2019

The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback

Benzinga.com  March 22, 2019

30 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  March 22, 2019

68 Biggest Movers From Yesterday

Benzinga.com  March 14, 2019

Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

GlobeNewswire March 13, 2019

40 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  March 13, 2019

The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings

Benzinga.com  March 8, 2019

Earnings Scheduled For March 8, 2019

Benzinga.com  March 8, 2019

The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Benzinga.com  December 7, 2018